M&A / Deals Merck KGaA and Remepy join forces to develop combo drug-digital therapies Pharmaceutical TechnologyMerck KGaA and Remepy will work in tandem to develop drug-digital therapy combinations for a rare cancer indication.Read full story pharminent April 28, 2026 (Last updated: April 29, 2026) Pharmaceutical Technology Merck KGaA and Remepy will work in tandem to develop drug-digital therapy combinations for a rare cancer indication. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Novartis shares fall as Entresto sales weakenNext: GSK eyes October FDA verdict on chronic hep B drug Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
